Safety and activity of combined radiotherapy (RT) and anti-PD-1 antibodies (PD-1) in patients (pts) with metastatic melanoma

E. Liniker; B. Kong; A. M. Menzies; A. Cooper; S. Ramanujam; S. Lo; R. F. Kefford; G. B. Fogarty; A. Guminski; T. W. Wang; M. S. Carlino; A. Hong; G. V. Long

doi:10.1016/S0959-8049(16)31821-4

Safety and activity of combined radiotherapy (RT) and anti-PD-1 antibodies (PD-1) in patients (pts) with metastatic melanoma

E. Liniker, B. Kong, A. M. Menzies, A. Cooper, S. Ramanujam, S. Lo, R. F. Kefford, G. B. Fogarty, A. Guminski, T. W. Wang, M. S. Carlino, A. Hong, G. V. Long

Research output: Contribution to journal › Meeting abstract

Original language	English
Article number	3302
Pages (from-to)	S664
Number of pages	1
Journal	European Journal of Cancer
Volume	51
Issue number	Supplement 3
DOIs	https://doi.org/10.1016/S0959-8049(16)31821-4
Publication status	Published - Sep 2015
Externally published	Yes
Event	European Cancer Congress - Vienna, Austria Duration: 25 Sep 2015 → 29 Sep 2015

Access to Document

10.1016/S0959-8049(16)31821-4

Cite this

Liniker, E., Kong, B., Menzies, A. M., Cooper, A., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A., Wang, T. W., Carlino, M. S., Hong, A., & Long, G. V. (2015). Safety and activity of combined radiotherapy (RT) and anti-PD-1 antibodies (PD-1) in patients (pts) with metastatic melanoma. European Journal of Cancer, 51(Supplement 3), S664. [3302]. https://doi.org/10.1016/S0959-8049(16)31821-4

Liniker, E. ; Kong, B. ; Menzies, A. M. ; Cooper, A. ; Ramanujam, S. ; Lo, S. ; Kefford, R. F. ; Fogarty, G. B. ; Guminski, A. ; Wang, T. W. ; Carlino, M. S. ; Hong, A. ; Long, G. V. / Safety and activity of combined radiotherapy (RT) and anti-PD-1 antibodies (PD-1) in patients (pts) with metastatic melanoma. In: European Journal of Cancer. 2015 ; Vol. 51, No. Supplement 3. pp. S664.

@article{3f0dce42d8494d82a7485d9f573c5b12,

title = "Safety and activity of combined radiotherapy (RT) and anti-PD-1 antibodies (PD-1) in patients (pts) with metastatic melanoma",

author = "E. Liniker and B. Kong and Menzies, {A. M.} and A. Cooper and S. Ramanujam and S. Lo and Kefford, {R. F.} and Fogarty, {G. B.} and A. Guminski and Wang, {T. W.} and Carlino, {M. S.} and A. Hong and Long, {G. V.}",

year = "2015",

month = sep,

doi = "10.1016/S0959-8049(16)31821-4",

language = "English",

volume = "51",

pages = "S664",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

number = "Supplement 3",

note = "European Cancer Congress ; Conference date: 25-09-2015 Through 29-09-2015",

}

Liniker, E, Kong, B, Menzies, AM, Cooper, A, Ramanujam, S, Lo, S, Kefford, RF, Fogarty, GB, Guminski, A, Wang, TW, Carlino, MS, Hong, A & Long, GV 2015, 'Safety and activity of combined radiotherapy (RT) and anti-PD-1 antibodies (PD-1) in patients (pts) with metastatic melanoma', European Journal of Cancer, vol. 51, no. Supplement 3, 3302, pp. S664. https://doi.org/10.1016/S0959-8049(16)31821-4

Safety and activity of combined radiotherapy (RT) and anti-PD-1 antibodies (PD-1) in patients (pts) with metastatic melanoma. / Liniker, E.; Kong, B.; Menzies, A. M.; Cooper, A.; Ramanujam, S.; Lo, S.; Kefford, R. F.; Fogarty, G. B.; Guminski, A.; Wang, T. W.; Carlino, M. S.; Hong, A.; Long, G. V.

In: European Journal of Cancer, Vol. 51, No. Supplement 3, 3302, 09.2015, p. S664.

Research output: Contribution to journal › Meeting abstract

TY - JOUR

T1 - Safety and activity of combined radiotherapy (RT) and anti-PD-1 antibodies (PD-1) in patients (pts) with metastatic melanoma

AU - Liniker, E.

AU - Kong, B.

AU - Menzies, A. M.

AU - Cooper, A.

AU - Ramanujam, S.

AU - Lo, S.

AU - Kefford, R. F.

AU - Fogarty, G. B.

AU - Guminski, A.

AU - Wang, T. W.

AU - Carlino, M. S.

AU - Hong, A.

AU - Long, G. V.

PY - 2015/9

Y1 - 2015/9

U2 - 10.1016/S0959-8049(16)31821-4

DO - 10.1016/S0959-8049(16)31821-4

M3 - Meeting abstract

VL - 51

SP - S664

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - Supplement 3

M1 - 3302

T2 - European Cancer Congress

Y2 - 25 September 2015 through 29 September 2015

ER -